

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:53:15 ON 07 MAR 2006

FILE 'REGISTRY' ENTERED AT 15:53:21 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with ZIC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3
DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See **HELP SLIMITS** for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10532677.str
```



chain nodes :

11 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20 23
chain bonds :

Chain bonds .
2-11 18-21

2-11 18-21
ring bonds

ring bonds :
 1-2 1-6 2-3 3-4 3-12 4-5 5-6 5-7 6-10 7-8 7-23 8-9 9-10 12-13 12-17
 13-14 14-15 15-16 16-17 16-18 17-20 18-19 19-20

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 3-12 4-5 7-23 16-18 17-20 18-19 18-21 19-20

normalized bonds :

5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17

G1:C, O, S, N

G2:O, N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 23:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 C, O, S, N

G2 O, N

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sample
SAMPLE SEARCH INITIATED 15:53:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 104 TO ITERATE

100.0% PROCESSED 104 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.03
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1469 TO 2691
PROJECTED ANSWERS: 68 TO 532
```

L2 15 SEA SSS SAM L1

```
=> s 11 full
FULL SEARCH INITIATED 15:53:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1962 TO ITERATE

100.0% PROCESSED 1962 ITERATIONS 347 ANSWERS
SEARCH TIME: 00.00.01
```

L3 347 SEA SSS FUL L1

```
=> file hcplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY 166.94 167.15
```

```
FILE 'HCPPLUS' ENTERED AT 15:54:03 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:53:15 ON 07 MAR 2006)

10/ 532,677

FILE 'REGISTRY' ENTERED AT 15:53:21 ON 07 MAR 2006

L1 STRUCTURE UPLOADED
L2 15 S L1 SAMPLE
L3 347 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:54:03 ON 07 MAR 2006


=> s 13
L4 1 L3

=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/ (N) :y


14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:390252 HCAPLUS
DOCUMENT NUMBER: 140:406823
TITLE: Preparation of quinoxaline derivatives as Cdk
inhibitors
INVENTOR(S): Hirai, Hiroshi; Kawanishi, Nobuhiko; Hirose, Masaaki;
Sugimoto, Tetsuya; Kamiyo, Kaorii; Shibata, Jun;
Masutani, Kouta
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl. 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039809	A1	20040513	WO 2003-JP13707	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MO, MW, MY, NZ, MC, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MD, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CZ, CY, CZ, DE, DK, EZ, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GH, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2503663	AA	20040513	CA 2003-2503663	20031027
AU 2003275681	A1	20040523	AU 2003-275681	20031027
EP 1557418	A1	20050727	EP 2003-758937	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HU, MY, AL, TR, BG, CZ, EE, HU, SE				
US 2006019959	A1	20060126	US 2005-523677	20050615
PRIORITY APPLN. INFO.:			JP 2002-313588	A 20021029
OTHER SOURCE(S):	MARPAT 140:406823		WO 2003-JP13707	W 20031027


GI



L4 ANSWER TO 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 688810-22-2p 688810-23-3p 688810-24-4p
 688810-25-5p 688810-26-6p 688810-27-7p
 688810-28-8p 688810-29-9p 689283-07-6p
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preps. of quinoxaline derivs. as Cdk inhibitors)
 RN 688005-13-5 CAPHLUS
 CN 7H-16, 18-(Iminomethano)-4,6-methanobif[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19, 21-dione, 8,9,10,11-tetrahydro- (SC1) (CA INDEX NAME)



RN 68806-14-6 HCPLUS
CN 7H-16,18-(1minomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 68806-15-7 HCPLUS
CN 7H-16,18-(imino(methano)-4,6-methanobenz[i,m][1,8,4,7,12]oxathistriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-, monohydrochloride, (11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. I [X is NH, S, or the like; Y is O or the like; ring B is -B1(B1')B2(B2')B3(B3')B4(B4')B5(B5')-, etc.; B1 - B5 are each independently CH, N, or the like; and B1' - B5' are each independently hydrogen or the like; and R is hydrogen, lower alkyl, or the like] are prepared. Compds. of this invention in vitro showed IC50 values of 1.6 nM to 34 nM against cyclin D2-cdk4.

688806-13-59 688806-14-56 688806-15-79
688806-16-59 688806-17-59 688806-18-09
688806-19-19 688806-20-49 688806-21-59
688806-22-69 688806-23-79 688806-24-89
688806-25-99 688806-26-09 688806-27-19
688806-28-29 688806-29-39 688806-30-69
688806-31-79 688806-32-89 688806-33-99
688806-34-09 688806-35-19 688806-36-29
688806-37-39 688806-38-49 688806-39-59
688806-40-59 688806-42-09 688806-44-29
688806-45-39 688806-46-49 688806-48-69
688806-50-09 688806-52-29 688806-54-49
688806-56-59 688806-58-59 688806-59-99
688806-60-29 688806-61-39 688806-62-99
688806-63-59 688806-65-69 688806-65-79
688806-66-69 688806-67-79 688806-68-99
688806-69-19 688806-70-49 688806-71-59
688806-72-69 688806-73-79 688806-74-89
688806-75-99 688806-76-09 688806-77-19
688806-78-29 688806-79-39 688806-80-69
688806-81-79 688806-82-99 688806-83-99
688806-84-09 688806-85-19 688806-86-29
688806-87-39 688806-88-49 688806-89-59
688806-90-69 688806-91-99 688806-92-09
688806-93-19 688806-94-29 688806-95-39
688806-96-49 688806-97-59 688806-98-69
688806-99-79 688806-00-39 688807-01-49
688807-02-59 688807-03-69 688807-04-79
688807-05-89 688807-06-99 688807-07-09
688807-08-19 688807-10-59 688807-12-79
688807-13-89 688807-13-09 688807-17-29
688807-19-49 688807-20-79 688807-21-89
688807-23-09 688807-25-29 688807-27-49
688807-28-79 688807-29-79 688807-31-09
688807-33-29 688807-34-39 688807-35-49
688807-37-69 688807-39-89 688807-41-29
688807-43-49 688807-45-69 688807-47-89
688807-49-09 688807-51-59 688807-53-69
688807-55-89 688807-57-09 688807-59-29
688807-61-69 688807-63-89 688807-65-09
688807-67-29 688807-69-49 688807-71-89
688807-73-09 688807-75-29 688807-77-49
688807-79-59 688807-81-09 688807-83-29
688807-84-39 688807-85-49 688807-86-69
688807-87-69 688807-88-79 688807-89-99
688807-90-19 688807-91-29 688807-92-99
688807-93-49 688807-94-59 688807-95-69
688807-96-79 688807-97-89 688807-98-99
688807-99-09 688807-10-29 688810-21-19


L4 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



• 16

RN 68806-16-8 HCPLUS
CN 7H-16,18-(Iminomethano)-4,6-methanodibenzo[1,m][1,8,4,7,12]oxathatriazacyclotetradecine-19,21-diene, 8,9,10,11-tetrahydro-11-methyl-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCII

RN 68806-17-9 HCPLUS
CN 7H-16,18-(Iminomethano)-4,6-methanodibenzo[i,m][1,8,4,7,12]oxathiatriazacycletotetradecine-19,21-dione, 8,9,10,11-tetrahydro-10-methyl-, monohydrochloride, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-18-0 HCPLUS

CN 7H-16,18-(iminomethano)-4,6-methanodibenz[i,j][1,8,4,7,12]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-9,11-dimethyl-, monohydrochloride, (11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-19-1 HCPLUS

CN 7H-16,18-(iminomethano)-4,6-methanodibenz[i,j][1,8,4,7,12]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-9,10-dimethyl-, monohydrochloride, (10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-22-6 HCPLUS

CN 17,19-(iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,9,12]oxathiadiazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-23-7 HCPLUS

CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(3R)-3-methoxy-1-piperidinyl]methyl-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-20-4 HCPLUS

CN 7H-16,18-(iminomethano)-4,6-methanodibenz[i,j][1,8,4,7,12]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-9,10-dimethyl-, monohydrochloride, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-21-5 HCPLUS

CN 7H-16,18-(iminomethano)-4,6-methanodibenz[i,j][1,8,4,7,12]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-9-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-24-8 HCPLUS

CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(3S)-3-methoxy-1-piperidinyl]methyl-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-25-9 HCPLUS

CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(4-morpholinyl)methyl-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-26-0 HCAPLUS
 CN 17,19-(iminomethano)-4,6,9,12-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-, monohydrochloride, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-27-1 HCAPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-(methoxymethyl)-1-piperidinyl)methyl]-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 688806-30-6 HCAPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 688806-31-7 HCAPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-22-(2-propenyl)-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 688806-28-2 HCAPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-(methoxymethyl)-1-piperidinyl)methyl]-22-methyl-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 688806-29-3 HCAPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-methoxy-1-piperidinyl)methyl]-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 688806-32-0 HCAPLUS
 CN 7H-7,10-Ethano-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,23-dione, 8,9,10,11-tetrahydro-14-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 688806-33-9 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-34-0 HCAPLUS
 CN 7H-16,18-(iminnomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotridecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (7S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-35-1 HCAPLUS
 CN 17,19-(iminnomethano)-4,6:7,10-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-, monohydrochloride, (7R,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-36-2 HCAPLUS
 CN 17,19-(iminnomethano)-4,6:7,10-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-, monohydrochloride, (7S,10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-37-3 HCAPLUS
 CN 17,19-(iminnomethano)-4,6:9,12-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-, monohydrochloride, (9R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-38-4 HCAPLUS
 CN 7H-16,18-(iminnomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotridecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (11R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-39-5 HCAPLUS
 CN 7H-16,18-(iminnomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotridecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-40-8 HCAPLUS
 CN 9,11-Epoxy-17,19-(iminnomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(2R)-2-(methoxymethyl)-1-piperidinyl]methyl-, monohydrochloride, (8S,11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-42-0 HCAPLUS
 CN 17,19-(iminnomethano)-4,6:9,12-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-methoxy-1-piperidinyl)methyl]-, (9R,12R)-, mono(trifluoroacetate), (9CI) (CA INDEX NAME)

CM 1

CRN 688806-41-9
 CMF C29 H32 N4 O4 S



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688806-44-2 HCAPLUS

CN 17,19-(Iminomethano)-4,6:9,12-dimethano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(2-methoxymethyl)-1-piperidinyl]methyl]-, (9R,12R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 688806-43-1
CHF C30 H34 N4 O4 S

Relative stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2

RN 688806-45-3 HCAPLUS

CN 17,19-(Iminomethano)-4,6:9,12-dimethano-16H-dibenz[b,f][1,8,4,9,12]oxathiatriazacyclopentadecine-20,23-dione, 7,8,9,11,12-tetrahydro-15-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-46-4 HCAPLUS

CN 17,19-(Iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathiatriazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(4-morpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 688806-48-6 HCAPLUS

CN 17,19-(Iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathiatriazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(3R)-3-methoxy-1-piperidinyl]methyl]-, (12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 688806-47-5
CHF C28 H31 N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688806-50-0 HCAPLUS

CN 17,19-(Iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathiatriazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(3S)-3-methoxy-1-piperidinyl]methyl]-, (12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 688806-49-7
CHF C28 H31 N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688806-52-2 HCPLUS

CN 17,19-(iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f]{1,8,4,9,12}oxathia triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(2R)-2-(methoxymethyl)-1-piperidinyl]methyl]-, (12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688806-51-1
CHF C29 H33 N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


CRN 688806-54-4 HCPLUS

CN 17,19-(iminomethano)-4,6:9,12-dimethano-10H-dibenz[b,f]{1,8,4,9,12}oxathia triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(2S)-2-(methoxymethyl)-1-piperidinyl]methyl]-, (12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688806-53-3
CHF C29 H33 N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688806-56-5 HCPLUS

CN 9,12-Ethano-17,19-(iminomethano)-4,6-methano-10H-dibenz[b,f]{1,8,4,9,12}oxathia triazacyclopentadecine-20,24-dione, 7,8,11,12-tetrahydro-15-[(3R)-3-methoxy-1-piperidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688806-55-5
CHF C29 H33 N5 O4 S

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2

RN 688806-58-8 HCPLUS

CN 9,12-Ethano-17,19-(iminomethano)-4,6-methano-10H-dibenz[b,f]{1,8,4,9,12}oxathia triazacyclopentadecine-20,24-dione, 7,8,11,12-tetrahydro-15-(4-morpholinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688806-57-7
CHF C27 H29 N5 O4 S


CH 2

CRN 76-05-1



RN 688806-59-5 HCPLUS


CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f]{1,8,4,9}oxathiadiazacyclette tridecene-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 688806-60-2 HCPLUS

CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f]{1,8,4,9}oxathiadiazacyclette tridecene-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(4-morpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 7H-16, 18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(4-methyl-1-piperidinyl)methyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-61-3 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 688806-62-4 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(2-(1-pyrrolidinyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 688806-63-5 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(2-(1-pyrrolidinyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-66-8 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688806-67-9 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 688806-64-6 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-10H-dibenz[b,f][1,8,4,9,12]oxathiatetradecine-20,23-dione, 7,8,11,12-tetrahydro-15-(methoxymethyl)-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 688806-65-7 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 688806-68-0 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-69-1 HCAPLUS
 CN 7H-16, 18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-70-4 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-71-5 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-72-6 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(4-morpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-73-7 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(2-methyl-1-pyrrolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-74-8 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(3-methyl-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 688806-75-9 HCPLUS
 CN 3-Piperidinecarboxylic acid, 1-[(8,9,10,11-tetrahydro-19,21-dioxo-7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecin-14-yl)methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 688806-76-0 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(2S)-2-(methoxymethyl)-1-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 688806-77-1 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(2A)-2-(methoxymethyl)-1-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688806-78-2 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(4-thiomorpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-79-3 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(4-methoxy-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-80-6 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(3-methoxy-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-81-7 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(3-methoxymethyl)-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-82-8 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-[(2-(methoxymethyl)-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-83-9 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 14-[(4,4-difluoro-1-piperidinyl)methyl]-8,9,10,11-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-84-0 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 14-[(4-fluoro-1-piperidinyl)methyl]-8,9,10,11-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 688806-85-1 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 14-[(diethylamino)methyl]-8,9,10,11-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 688806-94-2 HCAPLUS
 CN 17,19-(iminomethano)-4,6-methano-6H-dibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,22-dione, 7,8,9,10,11,12-hexahydro- (9CI) (CA INDEX NAME)



RN 688806-95-3 HCAPLUS
 CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HC1

RN 688806-96-4 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6:7,10-dimethanodibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-19,22-dione, 8,9,10,11-tetrahydro-, (7R,10S)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 688806-97-5 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[i,j][1,8,4,7,12]oxathiatriazacyclooctadecine-19,21-dione, 14-bromo-8,9,10,11-tetrahydro-9-methyl- (9CI) (CA INDEX NAME)




RN 688806-98-6 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-19,21-dione, 8,9,10,11-tetrahydro-13-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 688806-99-7 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-19,21-dione, 8,9,10,11-tetrahydro-13-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 688807-00-3 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitromethano)dibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-pyrimidinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)




RN 688807-01-4 HCAPLUS
 CN 7H-16,18-(iminomethano)-4,6:7,10-dimethanodibenz[b,f][1,8,4,9]oxathiadiazacyclopentadecine-19,22-dione, 13-[2-(4,4-difluoro-1-piperidinyl)ethyl]-8,9,10,11-tetrahydro- (9CI) (CA INDEX NAME)



RN 688807-02-5 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitromethano)dibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-pyrimidinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 688807-03-6 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-[5-(trifluoromethyl)-2-pyrimidinyl]-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 688807-04-7 HCPLUS



● HCl

RN 688807-06-9 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-methyl-2-pyrimidinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688807-07-0 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 15-(4,6-dimethyl-2-pyrimidinyl)-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(5-methyl-2-pyrimidinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688807-05-8 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(5,6,7,8-tetrahydro-2-quinazolinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCl

RN 688807-08-1 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-10-5 HCPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-pyridyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 688807-20-7 HCAPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f]{1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-
oxo-1-pyrrolidinyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-21-8 HCAPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f]{1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(1H-indol-1-
yl)-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688807-23-0 HCAPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f]{1,4,8,9,12]oxate

CH 1

CRN 688807-22-9
CHF C27 H27 N7 O3

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 688807-25-2 HCAPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f]{1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(1H-indazol-1-
yl)-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-24-1
CHF C29 H25 N7 O3

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 688807-27-4 HCAPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f]{1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(1H-
pyrrolo[2,3-b]pyridin-1-yl)-, (10R,12S)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CH 1

CRN 688807-26-3
CHF C29 H25 N7 O3

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2

RN 688807-28-5 HCPLUS
CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxate tetraazacyclopentadecine-20,23-dione, 15-(3,5-dimethylphenyl)-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688807-29-6 HCPLUS

CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate tetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(3-phenyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 688807-31-0 HCPLUS

CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate tetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(3-(trifluoromethoxy)phenyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-30-9
CHF C29 H24 F3 N5 O4

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-33-2 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate tetraazacyclopentadecine-20,23-dione, 15-(3,4-dimethoxyphenyl)-7,8,11,12-tetrahydro-10-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-32-1
CHF C30 H29 N5 O5

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688807-34-3 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate tetraazacyclopentadecine-20,23-dione, 15-(2,2-difluoro-1,3-benzodioxol-5-yl)-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688807-35-4 HCPLUS
 CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate triazacyclopentadecine-20,23-dione, 15-[4-(difluoromethoxy)phenyl]-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 688807-37-6 HCPLUS
 CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(3-methoxyphenyl)-10-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)



CH 2

CRN 76-05-1
 CHF C2 H F3 O2

RN 688807-41-2 HCPLUS
 CN Acetamide, N-[3-[(10R,12S)-7,8,11,12-tetrahydro-10-methyl-20,23-dioxo-5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate triazacyclopentadecin-15-yl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 688807-40-1
 CHF C30 H28 N6 O4

Absolute stereochemistry.

CH 1
 CRN 688807-36-5
 CHF C29 H27 N5 O4

Absolute stereochemistry.



CH 2
 CRN 76-05-1
 CHF C2 H F3 O2




RN 688807-39-8 HCPLUS
 CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate triazacyclopentadecine-20,23-dione, 15-(3-acetylphenyl)-7,8,11,12-tetrahydro-10-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-38-7
 CHF C30 H27 N5 O4

Absolute stereochemistry.



CH 2


CRN 76-05-1
 CHF C2 H F3 O2

RN 688807-43-4 HCPLUS
 CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(1-methylethyl)phenyl-, (10R,12S)-, m(10R,12S)-ono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-42-3
 CHF C31 H31 N5 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-45-6 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 15-(3,5-difluorophenyl)-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-44-5
CHF C28 H23 F2 N5 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-47-8 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(2-methoxyphenyl)-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-46-7
CHF C29 H27 N5 O4

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-49-0 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(4-methoxyphenyl)-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-48-9
CHF C29 H27 N5 O4

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-51-4 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazaacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-nitrophenyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-50-3
CHF C28 H24 N6 O5

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-53-6 HCAPLUS
 CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 triazacyclopentadecine-20,23-dione, 15-(4-aminophenyl)-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-52-5
CHF C28 H26 N6 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-55-8 HCAPLUS
 CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(4-hydroxyphenyl)-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-54-7
CHF C28 H25 N5 O4

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-57-0 HCAPLUS
 CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 triazacyclopentadecine-20,23-dione, 15-(3-aminophenyl)-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-56-9
CHF C28 H26 N6 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-59-2 HCAPLUS
 CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-(trifluoromethoxy)phenyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-58-1
CHF C29 H24 F3 N5 O4

Absolute stereochemistry.



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 68807-61-6 HCPLUS

CN Benzanide, N,N-dimethyl-4-[(10R,12S)-7,8,11,12-tetrahydro-10-methyl-20,23-dioxo-5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecin-15-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 68807-60-5
CMF C31 H30 N6 O4

Absolute stereochemistry.



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 68807-63-8 HCPLUS

CN Pyrrolidine, 1-[4-[(10R,12S)-7,8,11,12-tetrahydro-10-methyl-20,23-dioxo-5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecin-15-yl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 68807-62-7
CMF C33 H32 N6 O4

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 68807-65-0 HCPLUS
CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-(methylsulfonyl)phenyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 68807-64-9
CMF C29 H27 N5 O5 S

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 68807-67-2 HCPLUS
CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(1-pyrrolidinyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 68807-66-1
CMF C26 H28 N6 O3

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688807-69-4 HCPLUS

CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(2S)-2-
(methoxymethyl)-1-pyrrolidinyl]-10-methyl-, (10R,12S)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-68-3
CHF C28 H32 N6 O4

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2


RN 688807-71-8 HCPLUS

CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 15-(3-azabicyclo[3.2.2]non-3-yl)-
7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CH 1

CRN 688807-70-7
CHF C30 H34 N6 O3

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 688807-73-0 HCPLUS
CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(2R)-2-
(methoxymethyl)-1-pyrrolidinyl]-10-methyl-, (10R,12S)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-72-9
CHF C28 H32 N6 O4

Absolute stereochemistry.




CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 688807-75-2 HCPLUS
CN 5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-
methyl-1-piperidinyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CH 1

CRN 688807-74-1
CHF C28 H32 N6 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-77-4 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 15-(hexahydro-1H-azepin-1-yl)-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-76-3
CHF C28 H32 N6 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-79-6 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 15-(4-(2-fluorophenyl)-1-piperazinyl)-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-78-5
CHF C32 H32 F N7 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-81-0 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-(2-pyridinyl)-1-piperazinyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-80-9
CHF C31 H32 N8 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 688807-83-2 HCPLUS
CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-(phenylmethyl)-1-piperazinyl)-, (10R,12S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688807-82-1
CHF C33 H35 N7 O3


Absolute stereochemistry.



CH 2

CRN 76-05-1
CNF C2 H F3 O2RN 688807-84-3 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-14-(1-piperidinylmethyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-85-4 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-14-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-86-5 HCPLUS
CN Piperazine, 1-acetyl-4-[[((10R,12S)-7,8,11,12-tetrahydro-10-methyl-20,23-dioxo-5H,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxatetraazacyclopentadecin-14-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-87-6 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-88-7 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10,15-dimethyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-89-8 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-morpholinylmethyl)-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-90-1 HCPLUS
CN SH,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(methoxymethyl)-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-91-2 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-(2-methoxyethoxy)ethyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688807-92-3 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-[(2S)-tetrahydro-2H-pyran-2-yl]-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

RN 688807-94-5 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-methyl-, monohydrochloride, (12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-95-6 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-7,10-dimethyl-, monohydrochloride, (7S,10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-96-7 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 14-[(cyclopentylamino)methyl]-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 688807-93-4 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-[(2R)-tetrahydro-2H-pyran-2-yl]-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


Absolute stereochemistry.



● HCl

RN 688807-97-0 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 14-[(cyclopropylamino)methyl]-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 688807-98-9 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate trazacyclopentadecine-20,23-dione, 14-[(1,1-dimethylethyl)amino]methyl-7,8,11,12-tetrahydro-10-methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 688807-99-0 HCPLUS
 CN 5H,10H-17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,9,12]oxate triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-14-[(2,2,2-trifluoroethyl)amino]methyl-, monohydrochloride, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 688810-20-0 HCPLUS
 CN 7H,16,18-(Iminomethano)-4,6-methanodibenz[i,m][1,8,4,7,12]oxathia-triazacyclic-19,21-dione, 8,9,10,11-tetrahydro-9-methyl- (9CI) (CA INDEX NAME)




RN 688810-21-1 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(5-methyl-2-pyrimidinyl)-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688810-22-2 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(5,6,7,8-tetrahydro-2-quinazolinyl)-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688810-23-3 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(4-methyl-2-pyrimidinyl)-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688810-24-4 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688810-25-5 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-14-(1-piperidinylmethyl)-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688810-26-6 HCPLUS
 CN 17,19-(Iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 14-[(cyclopentylamino)methyl]-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688910-27-7 HCAPLUS
 CN 17,19-(Iminomethane)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 14-[(cyclopropylamino)methyl]-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 688910-28-8 HCAPLUS
 CN 17,19-(Iminomethane)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 14-[(1,1-dimethylethyl)amino)methyl]-7,8,11,12-tetrahydro-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CH₄


CRN 76-05-1
 CMF C2 H F3 O2



IT 688809-04-0P 688809-07-3P 688809-09-4P
 688809-09-5P 688809-28-8P 688809-29-9P
 688809-42-6P 688809-43-7P 688809-48-2P
 688809-49-3P 688809-50-6P 688809-51-7P
 688809-52-8P 688809-53-9P 688809-54-0P
 688809-55-1P 688809-56-2P 688809-60-8P
 688809-63-1P 688809-66-4P 688809-67-5P
 688809-70-0P 688809-71-1P 688809-72-2P
 688809-73-3P 688809-74-4P 688809-75-5P
 688809-76-6P 688809-77-7P 688809-78-8P
 688809-79-9P 688809-86-8P 688809-87-9P
 688809-88-0P 688809-89-1P 688809-90-4P
 688809-03-2P 688809-14-5P 688809-15-6P
 688809-16-7P 688809-18-9P 688809-19-0P
 688809-20-3P 688809-21-4P 688809-25-8P
 688809-26-9P 688809-27-0P 688809-32-7P
 688809-33-8P 688809-34-9P 688809-35-0P
 688809-36-1P 688809-37-2P 688809-38-3P
 688809-39-4P 688809-40-7P 688809-41-8P
 689283-08-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinoline derivs. as Cdk inhibitors)

RN 688809-04-0 HCAPLUS
 CN 7H-16,19-(Iminomethane)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclicotadecine-19,21-dione, 8,9,10,11-tetrahydro-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 688910-29-9 HCAPLUS
 CN 17,19-(Iminomethane)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(2,2,2-trifluoroethyl)amino)methyl]-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688283-07-6 HCAPLUS
 CN 17,19-(Iminomethane)-4,6:9,12-dimethano-10H-dibenz[b,f][1,8,4,9,12]oxathia-triazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-15-[(3-methoxy-1-piperidinyl)methyl]-, (12R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 688283-06-5
 CMF C28 H31 N5 O4 S

Absolute stereochemistry.




RN 688809-07-3 HCAPLUS
 CN 7H-16,19-(Iminomethane)-4,6-methanodibenz[i,m][1,8,4,7,12]oxathiadiazacyclicotadecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-9-[(4-nitrophenyl)sulfonyl]-20-[(2-(trimethylsilyl)ethoxy)methyl]-, (11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-08-4 HCAPLUS
 CN 7H-16,19-(Iminomethane)-4,6-methanodibenz[i,m][1,8,4,7,12]oxathiadiazacyclicotadecine-19,21-dione, 8,9,10,11-tetrahydro-11-methyl-20-[(2-(trimethylsilyl)ethoxy)methyl]-, (11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-09-5 HCAPIUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenzo[*i,c*][1,8,4,7,12]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-9,11-dimethyl-20-[(2-(trimethylsilyl)ethoxy)methyl]-, (11*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-28-8 HCAPIUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilomethano)dibenzo[*b,f*][1,4,8,9,12]oxatetraazacyclopentadecin-23-one, 7,8,9,10,11,12-hexahydro-15-(hydroxymethyl)-20-methoxy-, (12*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-29-9 HCAPIUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilomethano)dibenzo[*b,f*][1,4,8,9,12]oxatetraazacyclopentadecin-23-one, 7,8,9,10,11,12-tetrahydro-20-methoxy-15-[(3R)-3-methoxy-1-piperidinyl)methyl]-, (12*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-42-6 HCAPIUS
 CN 17,19-(iminomethano)-4,6:9,12-dimethano-6H-dibenzo[*b,f*][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(hydroxymethyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (9*S*,12*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-43-7 HCAPIUS
 CN 17,19-(iminomethano)-4,6:9,12-dimethano-6H-dibenzo[*b,f*][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (9*S*,12*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-48-2 HCAPIUS
 CN 8,11-Imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[*b,f*][1,8,4,9]oxathiadiazacyclopentadecine-22-carboxylic acid, 7,8,9,10,11,12-hexahydro-15-(hydroxymethyl)-20,23-dioxo-21-[(2-(trimethylsilyl)ethoxy)methyl]-, 2-propenyl ester, (8*S*,11*R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-49-3 HCAPIUS
 CN 8,11-Imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[*b,f*][1,8,4,9]oxathiadiazacyclopentadecine-22-carboxylic acid, 7,8,9,10,11,12-hexahydro-15-[(3-(methoxymethyl)-1-piperidinyl)methyl]-20,23-dioxo-21-[(2-(trimethylsilyl)ethoxy)methyl]-, 2-propenyl ester, (8*S*,11*R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-50-6 HCAPIUS
 CN 8,11-Imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[*b,f*][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-(methoxymethyl)-1-piperidinyl)methyl]-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (8*S*,11*R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-51-7 HCPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecine-22-carboxylic acid, 7,8,9,10,11,12-hexahydro-15-[(3-methoxy-1-piperidinyl)methyl]-20,23-dioxo-21-[(2-(trimethylsilyl)ethoxy)methyl]-, 2-propenyl ester, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-52-8 HCPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-[(3-methoxy-1-piperidinyl)methyl]-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-53-9 HCPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecine-22-carboxylic acid, 7,8,9,10,11,12-hexahydro-20,23-dioxo-15-(1-piperidinylmethyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, 2-propenyl ester, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-54-0 HCPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-55-1 HCPLUS
 CN 8,11-imino-17,19-(iminomethano)-4,6-methano-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecine-20,23-dione, 7,8,9,10,11,12-hexahydro-15-(1-piperidinylmethyl)-22-(2-propenyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (8S,11R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 688808-56-2 HCPLUS
 CN 7H-7,10-Ethano-16,18-(iminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,23-dione, 8,9,10,11-tetrahydro-14-(hydroxymethyl)-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-60-8 HCPLUS
 CN 8,11-Epoxy-4,6-methano-17,19-(nitrilmethano)-6H-dibenzo[b,f][1,8,4,9]oxathiadiazacyclopentadecin-23-one, 7,8,9,10,11,12-hexahydro-15-(hydroxymethyl)-20-methoxy-, (8S,11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-63-1 HCPLUS
 CN 7H-4,6:9,12-Dimethano-17,19-(nitrilmethano)dibenzo[e,i][1,4,11,7,12]dioxathiadiazacyclopentadecin-23-one, 8,9,11,12-tetrahydro-20-methoxy-15-[(tetrahydro-2H-pyran-2-yl)oxy)methyl]-, (9R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-66-4 HCAPLUS
 CN 4,6:9,12-Dimethano-17,19-(nitrilometheno)-10H-dibenzo[b,f][1,8,4,9,12]oxathiadiazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-15-(hydroxymethyl)-20-methoxy-, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688808-67-5 HCAPLUS
 CN 4,6:9,12-Dimethano-17,19-(nitrilometheno)-10H-dibenzo[b,f][1,8,4,9,12]oxathiadiazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-15-(hydroxymethyl)-20-methoxy-, (12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 688808-70-0 HCAPLUS
 CN 9,12-Etano-4,6-methano-17,19-(nitrilometheno)-10H-dibenzo[b,f][1,8,4,9,12]oxathiadiazacyclopentadecin-24-one, 7,8,11,12-tetrahydro-15-(hydroxymethyl)-20-methoxy- (9CI) (CA INDEX NAME)




RN 688808-71-1 HCAPLUS
 CN 7H-16,18-(aminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 14-bromo-8,9,10,11-tetrahydro-7-methyl-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-72-2 HCAPLUS
 CN 7H-16,18-(aminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-14-carboxylic acid, 8,9,10,11-tetrahydro-7-methyl-19,21-dioxo-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-73-3 HCAPLUS
 CN 7H-16,18-(aminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(hydroxymethyl)-7-methyl-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-74-4 HCAPLUS
 CN 7H-16,18-(aminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-14-carboxaldehyde, 8,9,10,11-tetrahydro-7-methyl-19,21-dioxo-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-75-5 HCAPLUS
 CN 7H-16,18-(aminomethano)-4,6-methanodibenzo[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(1-pyrrolidinylmethyl)-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-76-6 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-(4-methyl-1-piperazinyl)-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 688808-77-7 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 14-ethenyl-8,9,10,11-tetrahydro-7-methyl-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-78-8 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methanodibenz[b,f][1,8,4,9]oxathiadiazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-7-methyl-14-[(2-(1-pyrrolidinyl)ethyl)-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-79-9 HCPLUS
 CN 4,6,9,12-Dimethano-17,19-(nitrilometheno)-10H-dibenz[b,f][1,8,4,9,12]oxatriazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-15-(methoxymethyl)-, (12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 688808-86-8 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 14-bromo-8,9,10,11-tetrahydro-7-methyl-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-87-9 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-14-carboxylic acid, 8,9,10,11-tetrahydro-7-methyl-19,21-dioxo-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)







RN 688808-88-0 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-14-carboxaldehyde, 8,9,10,11-tetrahydro-7-methyl-19,21-dioxo-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-89-1 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-14-carboxylic acid, 8,9,10,11-tetrahydro-19,21-dioxo-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 688808-90-4 HCPLUS
 CN 7H-16,18-(iminomethano)-4,6-methano-5H-dibenz[b,f][1,4,8,9]oxatriazacyclotetradecine-19,21-dione, 8,9,10,11-tetrahydro-14-(hydroxymethyl)-20-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)






RN 68809-25-9 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 tetraazacyclopentadecine-20,23-dione, 15-bromo-7,8,11,12-tetrahydro-10-
 methyl-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (10R,12S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 68809-26-9 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 tetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-
 pyridinyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (10R,12S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 68809-27-0 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 tetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-10-methyl-15-(2-
 oxo-1-pyridinyl)-21-[(2-(trimethylsilyl)ethoxy)methyl]-, (10R,12S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68809-32-7 HCAPLUS
 CN SH,10H-17,19-(iminomethano)-4,6:9,12-dimethanodibenz[b,f][1,4,8,9,12]oxate
 tetraazacyclopentadecine-20,23-dione, 7,8,11,12-tetrahydro-14-
 (hydroxymethyl)-10-methyl-21-[(2-(trimethylsilyl)ethoxy)methyl]-,
 (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68809-33-8 HCAPLUS
 CN SH,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa
 tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-10-methyl-
 15-[(methylsulfonyl)methyl]-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68809-34-9 HCAPLUS
 CN SH,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa
 tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-10,15-
 dimethyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68809-35-0 HCAPLUS
 CN SH,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa
 tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-15-
 (methoxymethyl)-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68809-36-1 HCAPLUS
 CN SH,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa
 tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-15-(2-
 methoxymethyl)-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-37-2 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-15-[(1S)-1-hydroxy-3-butenyl]-20-methoxy-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-38-3 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-15-[(1R)-1-hydroxy-3-but enyl]-20-methoxy-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-39-4 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-10-methyl-15-[(1S)-1-(2-propenyl)-3-but enyl]-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-40-7 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 15-[(2S)-3,6-dihydro-2H-pyran-2-yl]-7,8,11,12-tetrahydro-20-methoxy-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 688809-41-8 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-20-methoxy-10-methyl-15-[(2S)-tetrahydro-2H-pyran-2-yl]-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689283-08-7 HCAPLUS
 CN 5H,10H-4,6:9,12-Dimethano-17,19-(nitrilometheno)dibenz[b,f][1,4,8,9,12]oxa tetraazacyclopentadecin-23-one, 7,8,11,12-tetrahydro-15-(1-hydroxy-3-but enyl)-20-methoxy-10-methyl-, (10R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT